Alto Neuroscience to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

Alto Neuroscience (NYSE: ANRO) announced its participation in the Jefferies Global Healthcare Conference in New York from June 5-6, 2024. Founder and CEO Amit Etkin, M.D., Ph.D., will engage in a fireside chat on June 6, 2024, at 2:30 p.m. ET. Additionally, the company's management will hold one-on-one meetings with investors. A live webcast of the discussion will be available on Alto's investor relations webpage, with a replay accessible afterward.

Positive

• Participation in a prestigious conference like Jefferies Global Healthcare may boost Alto Neuroscience's visibility.
• Engaging in one-on-one meetings with investors could foster investor relations and potentially attract new investments.
• Live webcast availability can enhance transparency and reach a broader audience, including stakeholders not attending the conference.

Negative

• The announcement lacks specific updates on financial performance or significant new developments, which may disappoint some investors.
• Participation in the conference alone may not be sufficient to impact the stock price significantly without additional substantial news.
• If the fireside chat fails to present new or compelling information, it could lead to investor dissatisfaction.

LOS ALTOS, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place June 5-6, 2024, in New York. Amit Etkin, M.D., Ph.D., founder and chief executive officer, will participate in a fireside chat on Thursday, June 6, 2024, at 2:30 p.m. ET, and management will host one-on-one meetings with investors.

A live webcast of the fireside chat will be available on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the conclusion of the event.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529163130/en/

Investor Contact:

Nick Smith

investors@altoneuroscience.com



Media Contact:

Jordann Merkert

media@altoneuroscience.com

Source: Alto Neuroscience, Inc.

FAQ

When will Alto Neuroscience participate in the Jefferies Global Healthcare Conference?

Alto Neuroscience will participate in the Jefferies Global Healthcare Conference on June 5-6, 2024.

What time is the fireside chat with CEO Amit Etkin?

The fireside chat with CEO Amit Etkin is scheduled for June 6, 2024, at 2:30 p.m. ET.

Where can I watch the live webcast of Alto Neuroscience's fireside chat?

The live webcast will be available on the Events and Presentations page in the Investors section of Alto’s website.

Will there be a replay available for the fireside chat?

Yes, a replay will be available after the conclusion of the event.

What is the stock symbol for Alto Neuroscience?

The stock symbol for Alto Neuroscience is ANRO.